Remember those rumors back in January about a big Quintiles IPO? Somebody had some good information. The global CRO filed its S-1 with the SEC this afternoon, outlining plans to go public in one of the biggest new industry offerings in quite some time.
INC Research has signed on to use goBalto's web-based software to boost the process of getting clinical trials up and running, providing the Bay Area startup with what appears to be one of its biggest customer wins yet for the tech.
Piramal Healthcare has accelerated its move into market access modeling by snapping up U.K. firm Abacus International for an undisclosed fee. The takeover comes months after India-based Piramal jumped into the sector by snagging Decision Resources Group for $635 million.
Tigermed Consulting, a CRO based in Shanghai, has opted to use Merge's CTMS for sponsors and CROs to efficiently advance studies.
After chopping deep into its R&D operations to scale back on expenses, AstraZeneca has struck a pact to outsource part of its drug discovery operations to a CRO in China. Pharmaron, which only recently snipped the ribbon at its new complex in Beijing, will play a supporting role on chemistry, drug metabolism and pharmacokinetics, and efficacy screening for the pharma giant in a multi-year deal announced over the weekend.
Nextrials has found a new partner to adopt its clinical trials software, which is tailored for the iPad. InClin, a clinical research organization, plans to use Nextrials' Prism software to speed the start of trials and push down costs of drug development.
India's biotech industry is better known for its contract research operations than novel drug development. But Advinus Pharma, a biotech company supported by the Tata group, is helping to change all that.
Under its private equity masters at Bain Capital and TPG Capital, Quintiles has been rapidly beefing up its clinical-to-commercial outsourcing operations around the globe. Now Bloomberg reports that the makeover may lead to one very big cash-out as Quintiles execs ponder filing an IPO.
Call it the bionic drug R&D group. Without scads of scientists on hand, AstraZeneca's virtual neuroscience unit relies heavily on information technologies to automate some of the heavy lifting of managing a pipeline of drugs for neurological and psychiatric disorders. In an interview with FierceBiotech IT, AZ research information head John Reynders described the tech platforms supporting the research group.
The global contract research group PRA has opened a second outpost in China as demand for clinical trials in Asia soars and the U.S.-based CRO's pharma customers set up their own operations in the country.